Business Context and Reporting Period
Keros Therapeutics, Inc. (KROS), a Delaware corporation, filed this Form 8-K on December 21, 2020. The company is an emerging growth company with its principal executive offices in Lexington, Massachusetts. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Key Financial Metrics
This filing is a Regulation FD disclosure regarding a corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material event reported is the Company's expectation to be added to the NASDAQ Biotechnology Index. This announcement was made via a press release issued on December 21, 2020, which is attached as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing incorporates a press release by reference but explicitly states that the information is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated. No specific financial guidance, management commentary on operational risks, or discussion of contingencies is provided within the text of this 8-K.
Investor Verification Checklist
- Verify the official announcement of inclusion in the NASDAQ Biotechnology Index via the attached press release (Exhibit 99.1).
- Confirm the effective date of the index addition, as the filing only states an "expectation."
- Review the Company's most recent 10-K or 10-Q for actual financial performance data, as this 8-K contains no financial metrics.